2-萘基甲酸酯 | 1988-18-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-萘基甲酸酯
• 英文名称: naphthalen-2-yl formate
• 英文别名: 2-naphthyl formate；β-Naphthyl-formiat
• CAS: 1988-18-7
• 化学式: C₁₁H₈O₂
• 分子量: 172.183
• InChiKey: ZSFLPNDWUWXOGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2915120000

反应信息

• 作为反应物：
  描述：

  2-萘基甲酸酯 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 2-萘酚
  参考文献：
  名称：

  The Baeyer-Villiger Oxidation of Aromatic Aldehydes and Ketones with Hydrogen Peroxide Catalyzed by Selenium Compounds. A Convenient Method for the Preparation of Phenols

  摘要：

  一系列有机硒化合物被研究作为过氧化氢在拜耳-维利格氧化反应中的活化剂。结果发现，这是一种方便且经济的转化具有聚合环系或供电子取代基的芳香醛、乙酰苯的多甲氧基衍生物为酚类的方法。该方法使用由芳硒酸活化的过氧化氢作为氧化剂。

  DOI：

  10.1055/s-1989-27183
• 作为产物：
  描述：

  2-萘甲醛 在 bis(o,p-dinitrophenyl) diselenide 双氧水 作用下， 以 二氯甲烷 为溶剂， 反应 80.0h， 生成 2-萘基甲酸酯
  参考文献：
  名称：

  The Baeyer-Villiger Oxidation of Aromatic Aldehydes and Ketones with Hydrogen Peroxide Catalyzed by Selenium Compounds. A Convenient Method for the Preparation of Phenols

  摘要：

  一系列有机硒化合物被研究作为过氧化氢在拜耳-维利格氧化反应中的活化剂。结果发现，这是一种方便且经济的转化具有聚合环系或供电子取代基的芳香醛、乙酰苯的多甲氧基衍生物为酚类的方法。该方法使用由芳硒酸活化的过氧化氢作为氧化剂。

  DOI：

  10.1055/s-1989-27183

文献信息

• [EN] ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2020229982A1

  公开（公告）日：2020-11-19

  The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof. Formula (I):

  本公开提供包含STING调节剂的抗体药物结合物。还提供了包含该抗体药物结合物的组合物。这些化合物和组合物对于刺激需要免疫反应的受试者是有用的。公式（I）:
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• [EN] FUSED QUINOLINE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE QUINOLINE FUSIONNÉE ET UTILISATION DE CELUI-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005105802A1

  公开（公告）日：2005-11-10

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein Rl is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s)) -carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and --- represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，并涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，可选地具有取代基的碳氢基团等；R3是未取代的（即缺失），氢原子等；R4和R5相同或不同，每个是氢原子，可选地具有取代基的碳氢基团等；R6是（环状基团，可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个是氢原子，卤素等；或R7和R8、R8和R9、以及R9和R10可以与相邻的碳原子一起形成环；n是1到5的整数；---表示未取代的（即缺失）或单键；---表示单键或双键，或其盐等。
• [EN] SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DE PIPÉRIDINE SUBSTITUÉE ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2017135306A1

  公开（公告）日：2017-08-10

  Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

  提供的是一种替代哌啶化合物，具有促进俐克脑肽2型受体激动剂活性。公式（I）所代表的化合物：其中每个符号如描述中所述，或其盐具有促进俐克脑肽2型受体激动剂活性，并且可用作嗜睡症的预防或治疗药物。
• FUROISOQUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1541576A1

  公开（公告）日：2005-06-15

  The present invention provides a compound represented by the formula    wherein A represents (1) a bond, (2) a group represented by the formula -CRa=CRb- (Ra and Rb each represent a hydrogen atom or C1-6 alkyl) and the like; R1 represents (1) cyano or (2) an optionally esterified or amidated carboxyl group; R2 represents (1) a hydrogen atom, (2) an optionally substituted hydroxy group, (3) an optionally substituted amino group and the like; R3 and R4 each represent a hydrogen atom and the like; R5 represents a hydrogen atom and the like; R6 represents an optionally substituted hydroxy group and the like; R7and R8 each represent an optionally substituted hydrocarbon group and the like; R9 and R10 each represent (1) a hydrogen atom and the like; Y represents an optionally substituted methylene group; and n represents 0 or 1, or a salt thereof, which has an excellent phosphodiesterase IV inhibiting action.

  本发明提供了一种化合物，其表示为式中的化合物，其中A代表（1）键，（2）由式 -CRa=CRb-（Ra和Rb分别代表氢原子或C1-6烷基等）表示的基团等；R1代表（1）氰基或（2）可选择酯化或酰胺化的羧基；R2代表（1）氢原子，（2）可选择取代的羟基，（3）可选择取代的氨基等；R3和R4各自代表氢原子等；R5代表氢原子等；R6代表可选择取代的羟基等；R7和R8各自代表可选择取代的碳氢基团等；R9和R10各自代表（1）氢原子等；Y代表可选择取代的亚甲基基团；n代表0或1，或其盐，具有优异的磷酸二酯酶IV抑制作用。